Document Detail

Choroidal neovascular membrane in persistent fetal vasculature syndrome managed with intravitreal pegaptanib sodium in an infant.
MedLine Citation:
PMID:  20419850     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The purpose of this study was to report the successful management of a case of choroidal neovascular membrane secondary to persistent fetal vasculature syndrome in an infant using intravitreal pegaptanib sodium (Macugen). METHODS: A 14-month-old male infant developed a peripapillary choroidal neovascular membrane 10 months after lens-sparing vitrectomy that he underwent for persistent fetal vasculature syndrome and confirmed on angiography and optical coherence tomography. A single dose of intravitreal pegaptanib sodium (0.3 mg) was administered after informed consent was obtained. Angiography and optical coherence tomography scans were performed at 6 and 14 weeks after the injection to determine the result. RESULTS: Six weeks after the single injection, the lesion reduced in size and exhibited less leakage on angiography. At 14 weeks, leakage was absent, and the lesion had involuted. CONCLUSION: Choroidal neovascular membrane in a case of persistent fetal vasculature syndrome is rare. This report shows that intravitreal pegaptanib sodium is highly effective in treating this lesion even in an infant.
Anand Vinekar; Newman Sund; Polly Quiram; Antonio Capone
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Retina (Philadelphia, Pa.)     Volume:  30     ISSN:  1539-2864     ISO Abbreviation:  Retina (Philadelphia, Pa.)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-23     Completed Date:  2010-06-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309919     Medline TA:  Retina     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S41-4     Citation Subset:  IM    
Department of Pediatric Retina, Narayana Nethralaya Postgraduate Institute of Ophthalmology, Bangalore, Karnataka, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aptamers, Nucleotide / therapeutic use*
Choroidal Neovascularization / diagnosis,  drug therapy*,  etiology,  physiopathology
Fluorescein Angiography
Persistent Hyperplastic Primary Vitreous / surgery*
Postoperative Complications*
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Vitreous Body
Reg. No./Substance:
0/Aptamers, Nucleotide; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Macular fibrosis in Coats disease.
Next Document:  Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive r...